Jackie Collins | Authors

PFS Benefit Observed With Tislelizumab Plus Chemotherapy for Advanced Squamous NSCLC

September 08, 2021

Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.